Read Detailed Profiles of Key Compounds in Development for Use in ...
PharmaLive.com (press release) - Newtown,PA,USA
Novartis oral Fingolimod (FTY720) goes some way to meet these needs and represents the most highly anticipated pipeline drug since the initial launch of ...
See all stories on this topic

Data to be presented at AAN Meeting -Study results of drug ...
PharmaLive.com (press release) - Newtown,PA,USA
The data suggest that FTY720 may have the potential to reduce neurodegeneration and enhance repair of the central nervous system (CNS) by modulating S1P ...
See all stories on this topic

Treatment with COPAXONE ® Plus Minocycline Showed Substantial ...
Business Wire (press release) - San Francisco,CA,USA
... active relapsing-remitting multiple sclerosis (RRMS), as measured by magnetic resonance imaging (MRI), compared to those receiving COPAXONE ® alone. ...
See all stories on this topic

No new reports of ills since return of Tysabri
Boston Globe - Boston,MA,USA
Ten months and 10000 patients after the multiple sclerosis drug Tysabri returned to the market, there have been no new cases of the potentially fatal brain ...
See all stories on this topic

Friday Newspaper Review - Irish Business News and International ...
FinFacts Ireland - Ireland
While welcoming the news, some analysts said it will require a longer duration of therapy to make neurologists comfortable with Tysabri's benefit/risk ...
See all stories on this topic

Downgrade Clips Biogen
TheStreet.com - USA
On Thursday, the company said new data confirmed the safety of Tysabri, a drug Biogen sells with Ireland's Elan (ELN - Cramer's Take - Stockpickr). ...
See all stories on this topic

Broker Action For Friday, May 4
Forbes - NY,USA
The biotech company announced Thursday that no new brain infections have been reported by patients using its drug Tysabri. Tysabri was taken off the market ...
See all stories on this topic

Preclinical Studies Suggest FTY720 Mechanisms In Multiple Sclerosis May Include Direct Activity In The Brain
Medical News Today Sat, 05 May 2007 6:04 AM PDT
New preclinical data, presented at the American Academy of Neurology (AAN) annual meeting in Boston, reflect the expanding understanding of FTY720's (fingolimod) mechanism of action in multiple sclerosis (MS), suggesting direct beneficial effects in the brain. [click link for full article]

Laquinimod cuts multiple sclerosis relapse: Study
PharmaBiz Fri, 04 May 2007 10:49 PM PDT
Teva Pharmaceutical Industries Ltd. and Active Biotech AB has announced that data from a 36-week, randomised, doubleblind, placebo-controlled phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 per cent in RRMS patients and was well tolerated.

Rituximab Reduced Disease Activity in MS Patients
HealthDay via Yahoo! News Fri, 04 May 2007 2:01 PM PDT
FRIDAY, May 4 (HealthDay News) -- The drug rituximab reduces disease activity in people with the relapsing-remitting form of multiple sclerosis (MS), according to two new studies.

Studies Suggest Investigational Agent Reduces Disease Activity In MS
Medical News Today Sat, 05 May 2007 0:06 AM PDT
A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 May 5, 2007. The drug reduced disease activity as indicated by MRI scans. [click link for full article]

Copaxone, Antibiotic Combination Could Help MS Sufferers
RedNova Fri, 04 May 2007 12:02 PM PDT
Teva Pharmaceuticals said a combination of Copaxone and antibiotic minocycline reduced brain lesions in patients with relapsing-remitting multiple sclerosis, compared to receiving Copaxone alone.

Secondhand Smoke Increases Risk Of Dementia
Medical News Today Sat, 05 May 2007 0:06 AM PDT
Exposure to secondhand tobacco smoke increases the risk of developing dementia, according to research that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 May 5, 2007. For the study, researchers evaluated 3,602 people age 65 and older in the Cardiovascular Health Study. [click link for full article]